© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept
Department of Medicine I, University of Heidelberg, Bergheimer Straße 58, Heidelberg 69115, Germany
* Corresponding author. Tel.: (+49-6221) 568604; Fax: (+49-6221) 564101.
Objective: This is the first part of a bipartite review that summarizes the rising knowledge on the molecular mechanisms underlying the action of advanced glycation endproducts (AGEs) and their contribution to diabetic complications and vascular disease. While the first part presented here focusses on AGE formation, the second part will describe the AGE-protein/receptor interactions and their role in mediating AGE-dependent intracellular signalling. Results: Nonenzymatic glycation, in which reducing sugars are covalently attached to free amino groups and ultimately form AGEs, has been found to occur during normal aging and at accelerated rate in diabetes mellitus. Oxidation, accompanying glycation in vivo, further supports chemical modifications. AGE formation and protein crosslinking are irreversible processes that alter the structural and functional properties of proteins, lipid components and nucleic acids. AGE modifications do not only change the physicochemical properties of the afflicted molecules, but also induce cellular signalling, activation of transcription factors and subsequent gene expression in vitro and in vivo. Conclusions: AGEs elicit a wide range of cell-mediated responses that might contribute to the pathogenesis of diabetic complications, vascular and renal disease and Alzheimer's disease. Substances that inhibit AGE formation, reduce oxidative stress or destroy already formed crosslinks may limit the progression of disease and may offer new tools for therapeutic interventions in the therapy of AGEs mediated disease.
KEYWORDS Advanced glycation endproducts; Diabetes mellitus; Vascular disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. K. Takahashi, K. Liu, H. Wake, S. Mori, J. Zhang, R. Liu, T. Yoshino, and M. Nishibori Prostaglandin E2 Inhibits Advanced Glycation End Product-Induced Adhesion Molecule Expression, Cytokine Production, and Lymphocyte Proliferation in Human Peripheral Blood Mononuclear Cells J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 656 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sundl, J. M. Roob, A. Meinitzer, B. Tiran, G. Khoschsorur, B. Haditsch, H. Holzer, and B. M. Winklhofer-Roob ANTIOXIDANT STATUS OF PATIENTS ON PERITONEAL DIALYSIS: ASSOCIATIONS WITH INFLAMMATION AND GLYCOXIDATIVE STRESS Perit. Dial. Int., January 1, 2009; 29(1): 89 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Minetti, L. Agati, and W. Malorni The microenvironment can shift erythrocytes from a friendly to a harmful behavior: Pathogenetic implications for vascular diseases Cardiovasc Res, July 1, 2007; 75(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Kaloudi, G. Basta, F. Perfetto, F. Bartoli, A. Del Rosso, I. Miniati, M. L. Conforti, S. Generini, S. Guiducci, R. Abbate, et al. Circulating levels of N{varepsilon}-(carboxymethyl)lysine are increased in systemic sclerosis Rheumatology, March 1, 2007; 46(3): 412 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Gallicchio, E. A. McRobert, A. Tikoo, M. E. Cooper, and L. A. Bach Advanced Glycation End Products Inhibit Tubulogenesis and Migration of Kidney Epithelial Cells in an Ezrin-Dependent Manner J. Am. Soc. Nephrol., February 1, 2006; 17(2): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Werstuck, M. I. Khan, G. Femia, A. J. Kim, V. Tedesco, B. Trigatti, and Y. Shi Glucosamine-Induced Endoplasmic Reticulum Dysfunction Is Associated With Accelerated Atherosclerosis in a Hyperglycemic Mouse Model Diabetes, January 1, 2006; 55(1): 93 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aragno, R. Mastrocola, C. Medana, F. Restivo, M. G. Catalano, N. Pons, O. Danni, and G. Boccuzzi Up-Regulation of Advanced Glycated Products Receptors in the Brain of Diabetic Rats Is Prevented by Antioxidant Treatment Endocrinology, December 1, 2005; 146(12): 5561 - 5567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Sengstock, P. V. Vaitkevicius, and M. A. Supiano Arterial Stiffness Is Related to Insulin Resistance in Nondiabetic Hypertensive Older Adults J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2823 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-T. Lin, Y.-Z. Tseng, and K.-C. Chang Aminoguanidine Prevents Fructose-Induced Arterial Stiffening in Wistar Rats: Aortic Impedance Analysis Experimental Biology and Medicine, November 1, 2004; 229(10): 1038 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Heidland, K Sebekova, A Frangiosa, L S De Santo, M Cirillo, F Rossi, M Cotrufo, A Perna, A Klassen, R Schinzel, et al. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation Heart, November 1, 2004; 90(11): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ziegler, C. G.H. Sohr, and J. Nourooz-Zadeh Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy Diabetes Care, September 1, 2004; 27(9): 2178 - 2183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. MARTA, Z. TOMAS, P. PETR, S. PAVEL, B. MARTIN, S. JIRINA, P. KVETA, and K.-E. ROSEMARIE ADVANCED GLYCATION END-PRODUCTS IN PATIENTS WITH CHRONIC ALCOHOL MISUSE Alcohol Alcohol., July 1, 2004; 39(4): 316 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Valencia, M. Mone, J. Zhang, M. Weetall, F. P. Buxton, and T. E. Hughes Divergent Pathways of Gene Expression Are Activated by the RAGE Ligands S100b and AGE-BSA Diabetes, March 1, 2004; 53(3): 743 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Roffi and E. J. Topol Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., February 1, 2004; 25(3): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kalousova, S. Sulkova, L. Fialova, J. Soukupova, I. M. Malbohan, P. Spacek, M. Braun, L. Mikulikova, M. Fortova, M. Horejsi, et al. Glycoxidation and inflammation in chronic haemodialysis patients Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2577 - 2581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K.M. Wong, A. I. Pettit, P. A. Quinn, S. C. Jennings, J. E. Davies, and L. L. Ng Advanced Glycation End Products Stimulate an Enhanced Neutrophil Respiratory Burst Mediated Through the Activation of Cytosolic Phospholipase A2 and Generation of Arachidonic Acid Circulation, October 14, 2003; 108(15): 1858 - 1864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Culbertson, E. I. Vassilenko, L. D. Morrison, and Keith. U. Ingold Paradoxical Impact of Antioxidants on Post-Amadori Glycoxidation: COUNTERINTUITIVE INCREASE IN THE YIELDS OF PENTOSIDINE AND N{epsilon}-CARBOXYMETHYLLYSINE USING A NOVEL MULTIFUNCTIONAL PYRIDOXAMINE DERIVATIVE J. Biol. Chem., October 3, 2003; 278(40): 38384 - 38394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Shaw, A. M. Schmidt, A. K. Banes, X. Wang, D. M. Stern, and M. B. Marrero S100B-RAGE-Mediated Augmentation of Angiotensin II-Induced Activation of JAK2 in Vascular Smooth Muscle Cells Is Dependent on PLD2 Diabetes, September 1, 2003; 52(9): 2381 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Morcos, A. A.R. Sayed, A. Bierhaus, B. Yard, R. Waldherr, W. Merz, I. Kloeting, E. Schleicher, S. Mentz, R. F. Abd el Baki, et al. Activation of Tubular Epithelial Cells in Diabetic Nephropathy Diabetes, December 1, 2002; 51(12): 3532 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Napoli, L. O. Lerman, F. de Nigris, J. Loscalzo, and L. J. Ignarro Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1515 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes Endocr. Rev., October 1, 2002; 23(5): 599 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K.M. Wong, A. I. Pettit, J. E. Davies, and L. L. Ng Augmentation of the Neutrophil Respiratory Burst Through the Action of Advanced Glycation End Products: A Potential Contributor to Vascular Oxidant Stress Diabetes, September 1, 2002; 51(9): 2846 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Facchiano, A. Lentini, V. Fogliano, S. Mancarella, C. Rossi, A. Facchiano, and M. C. Capogrossi Sugar-Induced Modification of Fibroblast Growth Factor 2 Reduces Its Angiogenic Activity in Vivo Am. J. Pathol., August 1, 2002; 161(2): 531 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Eckel, M. Wassef, A. Chait, B. Sobel, E. Barrett, G. King, M. Lopes-Virella, J. Reusch, N. Ruderman, G. Steiner, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of Atherosclerosis in Diabetes Circulation, May 7, 2002; 105 (18): e138 - e143. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Twigg, A. H. Joly, M. M. Chen, J. Tsubaki, H.-S. Kim, V. Hwa, Y. Oh, and R. G. Rosenfeld Connective Tissue Growth Factor/IGF-Binding Protein-Related Protein-2 Is a Mediator in the Induction of Fibronectin by Advanced Glycosylation End-Products in Human Dermal Fibroblasts Endocrinology, April 1, 2002; 143(4): 1260 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D.A. Stehouwer, M.-A. Gall, J. W.R. Twisk, E. Knudsen, J. J. Emeis, and H.-H. Parving Increased Urinary Albumin Excretion, Endothelial Dysfunction, and Chronic Low-Grade Inflammation in Type 2 Diabetes: Progressive, Interrelated, and Independently Associated With Risk of Death Diabetes, April 1, 2002; 51(4): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Bidasee, U. D. Dincer, and H. R. Besch Jr. Ryanodine Receptor Dysfunction in Hearts of Streptozotocin-Induced Diabetic Rats Mol. Pharmacol., December 1, 2001; 60(6): 1356 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Kloting, et al. Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-{kappa}B Diabetes, December 1, 2001; 50(12): 2792 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Xiang, R. Schinzel, A. Simm, G. Munch, K. Sebekova, M. Kasper, T. Niwa, C. Schmitz, and A. Heidland Advanced glycation end products (AGEs)-induced expression of TGF-{beta}1 is suppressed by a protease in the tubule cell line LLC-PK1 Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1562 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Twigg, M. M. Chen, A. H. Joly, S. D. Chakrapani, J. Tsubaki, H.-S. Kim, Y. Oh, and R. G. Rosenfeld Advanced Glycosylation End Products Up-Regulate Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein-Related Protein 2) in Human Fibroblasts: A Potential Mechanism for Expansion of Extracellular Matrix in Diabetes Mellitus Endocrinology, May 1, 2001; 142(5): 1760 - 1769. [Abstract] [Full Text]
|
|
|
|
|
|
N. Sakata, N. Uesugi, S. Takebayashi, R. Nagai, T. Jono, S. Horiuchi, M. Takeya, H. Itabe, T. Takano, T. Myint, et al. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis Cardiovasc Res, February 1, 2001; 49(2): 466 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Arking, A. Krebsova, M. Macek Sr., M. Macek Jr., A. Arking, I. S. Mian, L. Fried, A. Hamosh, S. Dey, I. McIntosh, et al. Association of human aging with a functional variant of klotho PNAS, January 22, 2002; 99(2): 856 - 861. [Abstract] [Full Text] [PDF]
|
|